Hematology

Tisagenlecleucel was shown to be effective in high-risk patients, including those who were heavily pretreated or had refractory disease.

The approval is supported by data from a global phase 3 trial assessing the use of the drug for individuals with previously untreated IDH1-mutated acute myeloid leukemia.

Aklilu Tedla, vice president of strategy and business development at Cardinal Health, discusses the cell and gene therapies in the pipeline for approval by the FDA.

After 14 months without ART, a patient with HIV only had transient detection of trace levels of HIV DNA in her blood cells after a stem cell transplant for acute myeloid leukemia.

An international phase 1/2 clinical trial is ongoing for the treatment for individuals with relapsed or refectory acute myeloid leukemia with FLT3 mutation.

Obinutuzumab is a CD20-directed cytolytic antibody used to treat certain types of blood cancer.

Omidubicel is a first-in-class, advanced nicotinamide-enabled stem cell therapy candidate being evaluated as the first potential allogeneic advanced cell therapy donor source for individuals with blood cancers in need of a transplant.

The advanced cell therapy is under development as an allogeneic hematopoietic stem cell transplant for patients with hematologic malignancies.

Voxelotor (Oxbryta) is a hemoglobin S polymerization inhibitor indicated for the treatment of sickle cell disease in adults and pediatric patients 4 years of age and older.

Scemblix is indicated for Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase, previously treated with 2 or more tyrosine kinase inhibitors.

DuoBody, for treatment of relapsed/refractory large B-cell lymphoma, demonstrates an overall response rate of 63.1%.

Investigational CAR T-cell therapy is currently being evaluated in an ongoing dose escalation phase 1 trial to analyze its safety and tolerability in treating non-Hodgkin lymphoma.

Drs Haumschild, Gilreath and Howe discuss the use of quality initiatives to support pharmacy accreditation through organizations such as URAC.

A panel of pharmacy experts explain what it means to provide quality oncology care for patients with myeloproliferative neoplasms (MPNs).

Asciminib offers a new option for patients harboring the T315I mutation.

David DeRemer, PharmD, BCOP, FCCP, FHOPA, a past-president on the board of Hematology/Oncology Pharmacy Association (HOPA), discusses key takeaways from the HOPA 2022 annual conference.

Sarah Wheeler, PharmD, BCOP, clinical pharmacy specialist in Hematology/Oncology at UF Health Shands Cancer Hospital, discusses some of the unique struggles that come from being an oncology pharmacist and a caregiver.

Results are from an exploratory analysis of 34 patients who received at least 1 dose after disease progression or suboptimal response with ruxolitinib monotherapy

Britny Brown, PharmD, BCOP, vice chair of the Hematology/Oncology Pharmacy Association (HOPA) DEI Task Force and clinical assistant professor at the University of Rhode Island College of Pharmacy, discusses the role of the task force within HOPA and its impact on the field more broadly.

Betrixaban (Bevyxxa) is a factor Xa inhibitor indicated for the prophylaxis of venous thromboembolism in adult patients.

Medication reconciliation and pharmacist counseling are crucial to clinical management of patients with hematologic malignancies.

Study captures the immune effect of the third dose of the COVID-19 vaccine in patients with plasma cell disorders and blood cancers.

Alpelisib is the first FDA-approved treatment for PROS, which is a range of rare conditions characterized by overgrowths and blood vessel anomalies.

Pharmacy workflow changes in the preparation of chemotherapy products can reduce patient chair time.

Axicabtagene ciloleucel (Yescarta) approved for patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or relapses within 12 months of first-line chemoimmunotherapy.